Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib + Sorafenib in Metastatic Renal Cell Carcinoma
NCT00467025Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2007
- Primary completion
- Apr 2010
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
01
Overview
Phase 2, randomised, double-blind trial of trebananib in renal cell carcinoma (RCC) (3 arms), sponsored by Amgen. Primary endpoint: Progression Free Survival at 2.75 years. Started May 2007; status: completed.
02
Drugs
trebananib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00467025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00467025.